Company intelligence / Profile preview
Spirovant Sciences
Philadelphia, Pennsylvania, United States
- Ownership
- Private
- Employees
- ~34
- Development stage
- Phase 1
01
Overview
Spirovant is developing gene therapies for cystic fibrosis and other respiratory diseases. Their lead program SPIRO-2101 has reached Phase 1/2 clinical trials, while other programs remain in preclinical development.
- Therapeutic areas
- Pulmonology
- Modalities
- Gene therapyAAV (adeno-associated virus) vectorslentiviral vectors
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Cystic Fibrosis Foundation
Beyond the preview
Go deeper on Spirovant Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spirovant Sciences.